nodes	percent_of_prediction	percent_of_DWPC	metapath
Entacapone—UGT1A9—Sorafenib—liver cancer	0.607	1	CbGbCtD
Entacapone—UGT1A9—Arylamine metabolism—NAT2—liver cancer	0.0103	0.0608	CbGpPWpGaD
Entacapone—UGT1A9—Glucuronidation—UGDH—liver cancer	0.00803	0.0475	CbGpPWpGaD
Entacapone—COMT—Estrogen metabolism—GSTA1—liver cancer	0.00721	0.0426	CbGpPWpGaD
Entacapone—UGT1A9—Glucuronidation—UGDH—liver cancer	0.00651	0.0385	CbGpPWpGaD
Entacapone—UGT1A9—Estrogen metabolism—GSTA1—liver cancer	0.00432	0.0255	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—UGDH—liver cancer	0.0041	0.0242	CbGpPWpGaD
Entacapone—COMT—Estrogen metabolism—GSTM1—liver cancer	0.00352	0.0208	CbGpPWpGaD
Entacapone—COMT—Estrogen metabolism—CYP1A1—liver cancer	0.00334	0.0197	CbGpPWpGaD
Entacapone—UGT1A9—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00317	0.0187	CbGpPWpGaD
Entacapone—UGT1A9—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00282	0.0167	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—UGDH—liver cancer	0.00246	0.0145	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—UGDH—liver cancer	0.0024	0.0142	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTA3—liver cancer	0.00235	0.0139	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12A—liver cancer	0.00217	0.0128	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTA4—liver cancer	0.00215	0.0127	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—GSTA2—liver cancer	0.00211	0.0125	CbGpPWpGaD
Entacapone—UGT1A9—Estrogen metabolism—GSTM1—liver cancer	0.00211	0.0125	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTA2—liver cancer	0.0021	0.0124	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTA1—liver cancer	0.00202	0.012	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—NAT2—liver cancer	0.002	0.0118	CbGpPWpGaD
Entacapone—UGT1A9—Estrogen metabolism—CYP1A1—liver cancer	0.002	0.0118	CbGpPWpGaD
Entacapone—UGT1A9—Irinotecan Pathway—APC—liver cancer	0.00191	0.0113	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—AHR—liver cancer	0.00184	0.0109	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—NFE2L2—liver cancer	0.0018	0.0106	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—DNAJB1—liver cancer	0.00164	0.00969	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—HPGDS—liver cancer	0.0016	0.00947	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—UGDH—liver cancer	0.00144	0.0085	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTA3—liver cancer	0.00141	0.00834	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—NR1H4—liver cancer	0.0014	0.00829	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTA3—liver cancer	0.00138	0.00815	CbGpPWpGaD
Entacapone—UGT1A9—PPAR Alpha Pathway—PPARA—liver cancer	0.00136	0.00806	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—liver cancer	0.00136	0.00805	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—GSTA3—liver cancer	0.00136	0.00803	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTA4—liver cancer	0.00129	0.00763	CbGpPWpGaD
Entacapone—COMT—Transmission across Chemical Synapses—GLUL—liver cancer	0.00129	0.00762	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTA4—liver cancer	0.00126	0.00745	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTA2—liver cancer	0.00126	0.00744	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—GSTA4—liver cancer	0.00124	0.00735	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTA2—liver cancer	0.00123	0.00726	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTA1—liver cancer	0.00121	0.00717	CbGpPWpGaD
Entacapone—UGT1A9—PPARA activates gene expression—NR1H4—liver cancer	0.0012	0.0071	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—NAT2—liver cancer	0.0012	0.00709	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GGT1—liver cancer	0.0012	0.00708	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTA1—liver cancer	0.00118	0.00701	CbGpPWpGaD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NR1H4—liver cancer	0.00117	0.00695	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—NAT2—liver cancer	0.00117	0.00693	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—NAT2—liver cancer	0.00116	0.00683	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTP1—liver cancer	0.00108	0.00636	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTM1—liver cancer	0.000989	0.00585	CbGpPWpGaD
Entacapone—COMT—Neuronal System—GLUL—liver cancer	0.000987	0.00584	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—GPX3—liver cancer	0.000982	0.00581	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—HPGDS—liver cancer	0.000959	0.00567	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.000943	0.00558	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—GSTA3—liver cancer	0.000941	0.00556	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—HPGDS—liver cancer	0.000936	0.00554	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—GSTA4—liver cancer	0.00086	0.00509	CbGpPWpGaD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CPT1B—liver cancer	0.000839	0.00496	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—NR1H4—liver cancer	0.000839	0.00496	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—GSTA2—liver cancer	0.000838	0.00496	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTA3—liver cancer	0.000825	0.00488	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—GSTA3—liver cancer	0.000814	0.00481	CbGpPWpGaD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—NR1H4—liver cancer	0.000809	0.00479	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—GSTA1—liver cancer	0.000809	0.00478	CbGpPWpGaD
Entacapone—UGT1A9—PPAR Alpha Pathway—CCND1—liver cancer	0.0008	0.00473	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—CYP2E1—liver cancer	0.000763	0.00451	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTA4—liver cancer	0.000755	0.00446	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—CYP2E1—liver cancer	0.000753	0.00445	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—GSTA4—liver cancer	0.000744	0.0044	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTA2—liver cancer	0.000735	0.00435	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GGT1—liver cancer	0.000718	0.00424	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—NFE2L2—liver cancer	0.000713	0.00422	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTA1—liver cancer	0.00071	0.0042	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—NAT2—liver cancer	0.000702	0.00415	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GGT1—liver cancer	0.000701	0.00414	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—NAT2—liver cancer	0.000692	0.00409	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—GPX3—liver cancer	0.00068	0.00402	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—TGFA—liver cancer	0.00068	0.00402	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—SERPINA1—liver cancer	0.00067	0.00396	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTP1—liver cancer	0.000645	0.00381	CbGpPWpGaD
Entacapone—UGT1A9—PPAR Alpha Pathway—MYC—liver cancer	0.000642	0.0038	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTP1—liver cancer	0.000629	0.00372	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—GSTP1—liver cancer	0.000621	0.00367	CbGpPWpGaD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CRABP1—liver cancer	0.000619	0.00366	CbGpPWpGaD
Entacapone—Cramps of lower extremities—Doxorubicin—liver cancer	0.000616	0.00275	CcSEcCtD
Entacapone—Dyspepsia—Sorafenib—liver cancer	0.000616	0.00275	CcSEcCtD
Entacapone—Oesophagitis—Doxorubicin—liver cancer	0.000613	0.00274	CcSEcCtD
Entacapone—Phlebitis—Epirubicin—liver cancer	0.000611	0.00273	CcSEcCtD
Entacapone—Rash maculo-papular—Doxorubicin—liver cancer	0.000609	0.00272	CcSEcCtD
Entacapone—Decreased appetite—Sorafenib—liver cancer	0.000608	0.00272	CcSEcCtD
Entacapone—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000605	0.0027	CcSEcCtD
Entacapone—Gastrointestinal disorder—Sorafenib—liver cancer	0.000604	0.0027	CcSEcCtD
Entacapone—Fatigue—Sorafenib—liver cancer	0.000603	0.00269	CcSEcCtD
Entacapone—Hepatic function abnormal—Epirubicin—liver cancer	0.000602	0.00269	CcSEcCtD
Entacapone—Pain—Sorafenib—liver cancer	0.000598	0.00267	CcSEcCtD
Entacapone—Constipation—Sorafenib—liver cancer	0.000598	0.00267	CcSEcCtD
Entacapone—UGT1A9—Phase II conjugation—GSTM1—liver cancer	0.000592	0.0035	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—GPX3—liver cancer	0.000588	0.00348	CbGpPWpGaD
Entacapone—Vascular purpura—Epirubicin—liver cancer	0.000588	0.00263	CcSEcCtD
Entacapone—Hepatic failure—Epirubicin—liver cancer	0.000585	0.00262	CcSEcCtD
Entacapone—Eczema—Epirubicin—liver cancer	0.000585	0.00262	CcSEcCtD
Entacapone—Mental disability—Doxorubicin—liver cancer	0.000582	0.0026	CcSEcCtD
Entacapone—COMT—Biological oxidations—GSTM1—liver cancer	0.000578	0.00342	CbGpPWpGaD
Entacapone—Gastrointestinal pain—Sorafenib—liver cancer	0.000572	0.00256	CcSEcCtD
Entacapone—COMT—Metapathway biotransformation—GSTM1—liver cancer	0.00057	0.00337	CbGpPWpGaD
Entacapone—Phlebitis—Doxorubicin—liver cancer	0.000565	0.00252	CcSEcCtD
Entacapone—Hot flush—Epirubicin—liver cancer	0.000562	0.00251	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—HPGDS—liver cancer	0.000561	0.00332	CbGpPWpGaD
Entacapone—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00056	0.0025	CcSEcCtD
Entacapone—Menopausal symptoms—Epirubicin—liver cancer	0.000557	0.00249	CcSEcCtD
Entacapone—Hepatic function abnormal—Doxorubicin—liver cancer	0.000557	0.00249	CcSEcCtD
Entacapone—Urticaria—Sorafenib—liver cancer	0.000556	0.00248	CcSEcCtD
Entacapone—Body temperature increased—Sorafenib—liver cancer	0.000553	0.00247	CcSEcCtD
Entacapone—Abdominal pain—Sorafenib—liver cancer	0.000553	0.00247	CcSEcCtD
Entacapone—Dermatitis bullous—Epirubicin—liver cancer	0.00055	0.00246	CcSEcCtD
Entacapone—COMT—Biological oxidations—CYP1A1—liver cancer	0.000548	0.00324	CbGpPWpGaD
Entacapone—Purpura—Epirubicin—liver cancer	0.000546	0.00244	CcSEcCtD
Entacapone—Vascular purpura—Doxorubicin—liver cancer	0.000544	0.00243	CcSEcCtD
Entacapone—Hepatic failure—Doxorubicin—liver cancer	0.000542	0.00242	CcSEcCtD
Entacapone—Eczema—Doxorubicin—liver cancer	0.000542	0.00242	CcSEcCtD
Entacapone—COMT—Metapathway biotransformation—CYP1A1—liver cancer	0.000541	0.0032	CbGpPWpGaD
Entacapone—Hypoglycaemia—Epirubicin—liver cancer	0.000539	0.00241	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.000531	0.00314	CbGpPWpGaD
Entacapone—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000526	0.00235	CcSEcCtD
Entacapone—Pain in extremity—Epirubicin—liver cancer	0.000526	0.00235	CcSEcCtD
Entacapone—Diplopia—Epirubicin—liver cancer	0.000526	0.00235	CcSEcCtD
Entacapone—Hot flush—Doxorubicin—liver cancer	0.00052	0.00232	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.00052	0.00308	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000519	0.00307	CbGpPWpGaD
Entacapone—Menopausal symptoms—Doxorubicin—liver cancer	0.000516	0.0023	CcSEcCtD
Entacapone—Hypersensitivity—Sorafenib—liver cancer	0.000515	0.0023	CcSEcCtD
Entacapone—Dermatitis bullous—Doxorubicin—liver cancer	0.000509	0.00228	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.000506	0.00299	CbGpPWpGaD
Entacapone—Purpura—Doxorubicin—liver cancer	0.000505	0.00226	CcSEcCtD
Entacapone—Asthenia—Sorafenib—liver cancer	0.000502	0.00224	CcSEcCtD
Entacapone—Hypoglycaemia—Doxorubicin—liver cancer	0.000499	0.00223	CcSEcCtD
Entacapone—Pruritus—Sorafenib—liver cancer	0.000495	0.00221	CcSEcCtD
Entacapone—Ataxia—Epirubicin—liver cancer	0.000495	0.00221	CcSEcCtD
Entacapone—Blood creatinine increased—Epirubicin—liver cancer	0.000493	0.0022	CcSEcCtD
Entacapone—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000487	0.00217	CcSEcCtD
Entacapone—Diplopia—Doxorubicin—liver cancer	0.000487	0.00217	CcSEcCtD
Entacapone—Pain in extremity—Doxorubicin—liver cancer	0.000487	0.00217	CcSEcCtD
Entacapone—Orthostatic hypotension—Epirubicin—liver cancer	0.00048	0.00215	CcSEcCtD
Entacapone—Diarrhoea—Sorafenib—liver cancer	0.000479	0.00214	CcSEcCtD
Entacapone—UGT1A9—NRF2 pathway—GGT1—liver cancer	0.000479	0.00283	CbGpPWpGaD
Entacapone—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000474	0.00212	CcSEcCtD
Entacapone—UGT1A9—PPARA activates gene expression—CYP1A1—liver cancer	0.00047	0.00278	CbGpPWpGaD
Entacapone—Gastritis—Epirubicin—liver cancer	0.000466	0.00208	CcSEcCtD
Entacapone—Muscular weakness—Epirubicin—liver cancer	0.000464	0.00207	CcSEcCtD
Entacapone—Dizziness—Sorafenib—liver cancer	0.000463	0.00207	CcSEcCtD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CYP1A1—liver cancer	0.00046	0.00272	CbGpPWpGaD
Entacapone—Ataxia—Doxorubicin—liver cancer	0.000458	0.00204	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—CYP2E1—liver cancer	0.000457	0.0027	CbGpPWpGaD
Entacapone—Blood creatinine increased—Doxorubicin—liver cancer	0.000456	0.00204	CcSEcCtD
Entacapone—Dysphagia—Epirubicin—liver cancer	0.000455	0.00203	CcSEcCtD
Entacapone—UGT1A9—Metapathway biotransformation—CYP2E1—liver cancer	0.000451	0.00267	CbGpPWpGaD
Entacapone—Vomiting—Sorafenib—liver cancer	0.000445	0.00199	CcSEcCtD
Entacapone—Orthostatic hypotension—Doxorubicin—liver cancer	0.000445	0.00199	CcSEcCtD
Entacapone—Angina pectoris—Epirubicin—liver cancer	0.000443	0.00198	CcSEcCtD
Entacapone—Rash—Sorafenib—liver cancer	0.000441	0.00197	CcSEcCtD
Entacapone—Dermatitis—Sorafenib—liver cancer	0.000441	0.00197	CcSEcCtD
Entacapone—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000438	0.00196	CcSEcCtD
Entacapone—Headache—Sorafenib—liver cancer	0.000438	0.00196	CcSEcCtD
Entacapone—Gastritis—Doxorubicin—liver cancer	0.000431	0.00192	CcSEcCtD
Entacapone—UGT1A9—NRF2 pathway—GSTP1—liver cancer	0.00043	0.00254	CbGpPWpGaD
Entacapone—UGT1A9—PPARA activates gene expression—PPARA—liver cancer	0.00043	0.00254	CbGpPWpGaD
Entacapone—Muscular weakness—Doxorubicin—liver cancer	0.000429	0.00192	CcSEcCtD
Entacapone—Dysuria—Epirubicin—liver cancer	0.000425	0.0019	CcSEcCtD
Entacapone—UGT1A9—NRF2 pathway—HMOX1—liver cancer	0.000424	0.00251	CbGpPWpGaD
Entacapone—Upper respiratory tract infection—Epirubicin—liver cancer	0.000423	0.00189	CcSEcCtD
Entacapone—Dysphagia—Doxorubicin—liver cancer	0.000421	0.00188	CcSEcCtD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARA—liver cancer	0.00042	0.00249	CbGpPWpGaD
Entacapone—Pollakiuria—Epirubicin—liver cancer	0.00042	0.00188	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—GGT1—liver cancer	0.00042	0.00248	CbGpPWpGaD
Entacapone—Nausea—Sorafenib—liver cancer	0.000416	0.00186	CcSEcCtD
Entacapone—Weight increased—Epirubicin—liver cancer	0.000414	0.00185	CcSEcCtD
Entacapone—Weight decreased—Epirubicin—liver cancer	0.000411	0.00184	CcSEcCtD
Entacapone—COMT—Metabolism—UGDH—liver cancer	0.00041	0.00243	CbGpPWpGaD
Entacapone—Hyperglycaemia—Epirubicin—liver cancer	0.00041	0.00183	CcSEcCtD
Entacapone—Angina pectoris—Doxorubicin—liver cancer	0.00041	0.00183	CcSEcCtD
Entacapone—Pneumonia—Epirubicin—liver cancer	0.000408	0.00182	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000406	0.0024	CbGpPWpGaD
Entacapone—Neuropathy peripheral—Epirubicin—liver cancer	0.000397	0.00178	CcSEcCtD
Entacapone—UGT1A9—NRF2 pathway—GSTM1—liver cancer	0.000395	0.00234	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—HGF—liver cancer	0.000395	0.00234	CbGpPWpGaD
Entacapone—Conjunctivitis—Epirubicin—liver cancer	0.000394	0.00176	CcSEcCtD
Entacapone—Urinary tract infection—Epirubicin—liver cancer	0.000394	0.00176	CcSEcCtD
Entacapone—Dysuria—Doxorubicin—liver cancer	0.000393	0.00176	CcSEcCtD
Entacapone—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000391	0.00175	CcSEcCtD
Entacapone—Sweating—Epirubicin—liver cancer	0.000389	0.00174	CcSEcCtD
Entacapone—Pollakiuria—Doxorubicin—liver cancer	0.000389	0.00174	CcSEcCtD
Entacapone—Haematuria—Epirubicin—liver cancer	0.000386	0.00173	CcSEcCtD
Entacapone—COMT—Metabolism—EPT1—liver cancer	0.000386	0.00228	CbGpPWpGaD
Entacapone—Hepatobiliary disease—Epirubicin—liver cancer	0.000383	0.00171	CcSEcCtD
Entacapone—Weight increased—Doxorubicin—liver cancer	0.000383	0.00171	CcSEcCtD
Entacapone—Epistaxis—Epirubicin—liver cancer	0.000382	0.00171	CcSEcCtD
Entacapone—Weight decreased—Doxorubicin—liver cancer	0.000381	0.0017	CcSEcCtD
Entacapone—Sinusitis—Epirubicin—liver cancer	0.00038	0.0017	CcSEcCtD
Entacapone—Hyperglycaemia—Doxorubicin—liver cancer	0.000379	0.0017	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.000379	0.00224	CbGpPWpGaD
Entacapone—Agranulocytosis—Epirubicin—liver cancer	0.000378	0.00169	CcSEcCtD
Entacapone—Pneumonia—Doxorubicin—liver cancer	0.000377	0.00169	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—GSTP1—liver cancer	0.000377	0.00223	CbGpPWpGaD
Entacapone—UGT1A9—Metapathway biotransformation—GSTP1—liver cancer	0.000372	0.0022	CbGpPWpGaD
Entacapone—Bradycardia—Epirubicin—liver cancer	0.00037	0.00166	CcSEcCtD
Entacapone—Neuropathy peripheral—Doxorubicin—liver cancer	0.000368	0.00164	CcSEcCtD
Entacapone—Haemoglobin—Epirubicin—liver cancer	0.000366	0.00163	CcSEcCtD
Entacapone—COMT—Metabolism—TAT—liver cancer	0.000366	0.00216	CbGpPWpGaD
Entacapone—Urinary tract infection—Doxorubicin—liver cancer	0.000365	0.00163	CcSEcCtD
Entacapone—Conjunctivitis—Doxorubicin—liver cancer	0.000365	0.00163	CcSEcCtD
Entacapone—Hepatitis—Epirubicin—liver cancer	0.000364	0.00163	CcSEcCtD
Entacapone—Haemorrhage—Epirubicin—liver cancer	0.000364	0.00163	CcSEcCtD
Entacapone—Hypoaesthesia—Epirubicin—liver cancer	0.000362	0.00162	CcSEcCtD
Entacapone—Pharyngitis—Epirubicin—liver cancer	0.000361	0.00161	CcSEcCtD
Entacapone—Sweating—Doxorubicin—liver cancer	0.00036	0.00161	CcSEcCtD
Entacapone—Urinary tract disorder—Epirubicin—liver cancer	0.000359	0.00161	CcSEcCtD
Entacapone—COMT—Transmission across Chemical Synapses—BRAF—liver cancer	0.000358	0.00212	CbGpPWpGaD
Entacapone—Haematuria—Doxorubicin—liver cancer	0.000358	0.0016	CcSEcCtD
Entacapone—Urethral disorder—Epirubicin—liver cancer	0.000357	0.00159	CcSEcCtD
Entacapone—UGT1A9—PPARA activates gene expression—PPARG—liver cancer	0.000355	0.0021	CbGpPWpGaD
Entacapone—Hepatobiliary disease—Doxorubicin—liver cancer	0.000355	0.00158	CcSEcCtD
Entacapone—Epistaxis—Doxorubicin—liver cancer	0.000354	0.00158	CcSEcCtD
Entacapone—Sinusitis—Doxorubicin—liver cancer	0.000352	0.00157	CcSEcCtD
Entacapone—Visual impairment—Epirubicin—liver cancer	0.000351	0.00157	CcSEcCtD
Entacapone—Agranulocytosis—Doxorubicin—liver cancer	0.00035	0.00156	CcSEcCtD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—liver cancer	0.000348	0.00206	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTM1—liver cancer	0.000347	0.00205	CbGpPWpGaD
Entacapone—Erythema multiforme—Epirubicin—liver cancer	0.000344	0.00154	CcSEcCtD
Entacapone—Bradycardia—Doxorubicin—liver cancer	0.000343	0.00153	CcSEcCtD
Entacapone—UGT1A9—Metapathway biotransformation—GSTM1—liver cancer	0.000342	0.00202	CbGpPWpGaD
Entacapone—Eye disorder—Epirubicin—liver cancer	0.00034	0.00152	CcSEcCtD
Entacapone—Haemoglobin—Doxorubicin—liver cancer	0.000338	0.00151	CcSEcCtD
Entacapone—Flushing—Epirubicin—liver cancer	0.000338	0.00151	CcSEcCtD
Entacapone—Cardiac disorder—Epirubicin—liver cancer	0.000338	0.00151	CcSEcCtD
Entacapone—Haemorrhage—Doxorubicin—liver cancer	0.000337	0.0015	CcSEcCtD
Entacapone—Hepatitis—Doxorubicin—liver cancer	0.000337	0.0015	CcSEcCtD
Entacapone—Hypoaesthesia—Doxorubicin—liver cancer	0.000335	0.0015	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000334	0.00198	CbGpPWpGaD
Entacapone—Pharyngitis—Doxorubicin—liver cancer	0.000334	0.00149	CcSEcCtD
Entacapone—Urinary tract disorder—Doxorubicin—liver cancer	0.000333	0.00149	CcSEcCtD
Entacapone—Urethral disorder—Doxorubicin—liver cancer	0.00033	0.00147	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—CYP1A1—liver cancer	0.000328	0.00194	CbGpPWpGaD
Entacapone—Visual impairment—Doxorubicin—liver cancer	0.000324	0.00145	CcSEcCtD
Entacapone—UGT1A9—Metapathway biotransformation—CYP1A1—liver cancer	0.000324	0.00192	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000322	0.00191	CbGpPWpGaD
Entacapone—Alopecia—Epirubicin—liver cancer	0.000322	0.00144	CcSEcCtD
Entacapone—Mental disorder—Epirubicin—liver cancer	0.000319	0.00142	CcSEcCtD
Entacapone—Erythema multiforme—Doxorubicin—liver cancer	0.000318	0.00142	CcSEcCtD
Entacapone—Malnutrition—Epirubicin—liver cancer	0.000317	0.00142	CcSEcCtD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—liver cancer	0.000317	0.00187	CbGpPWpGaD
Entacapone—Eye disorder—Doxorubicin—liver cancer	0.000315	0.00141	CcSEcCtD
Entacapone—Flushing—Doxorubicin—liver cancer	0.000312	0.0014	CcSEcCtD
Entacapone—Cardiac disorder—Doxorubicin—liver cancer	0.000312	0.0014	CcSEcCtD
Entacapone—Flatulence—Epirubicin—liver cancer	0.000312	0.00139	CcSEcCtD
Entacapone—Tension—Epirubicin—liver cancer	0.000311	0.00139	CcSEcCtD
Entacapone—Dysgeusia—Epirubicin—liver cancer	0.00031	0.00139	CcSEcCtD
Entacapone—Nervousness—Epirubicin—liver cancer	0.000308	0.00137	CcSEcCtD
Entacapone—Back pain—Epirubicin—liver cancer	0.000306	0.00137	CcSEcCtD
Entacapone—Muscle spasms—Epirubicin—liver cancer	0.000305	0.00136	CcSEcCtD
Entacapone—COMT—Transmission across Chemical Synapses—RAF1—liver cancer	0.000299	0.00177	CbGpPWpGaD
Entacapone—Vision blurred—Epirubicin—liver cancer	0.000299	0.00133	CcSEcCtD
Entacapone—Alopecia—Doxorubicin—liver cancer	0.000298	0.00133	CcSEcCtD
Entacapone—Mental disorder—Doxorubicin—liver cancer	0.000295	0.00132	CcSEcCtD
Entacapone—Ill-defined disorder—Epirubicin—liver cancer	0.000294	0.00131	CcSEcCtD
Entacapone—Malnutrition—Doxorubicin—liver cancer	0.000293	0.00131	CcSEcCtD
Entacapone—Agitation—Epirubicin—liver cancer	0.000291	0.0013	CcSEcCtD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARA—liver cancer	0.00029	0.00171	CbGpPWpGaD
Entacapone—Flatulence—Doxorubicin—liver cancer	0.000289	0.00129	CcSEcCtD
Entacapone—Tension—Doxorubicin—liver cancer	0.000288	0.00129	CcSEcCtD
Entacapone—Dysgeusia—Doxorubicin—liver cancer	0.000287	0.00128	CcSEcCtD
Entacapone—Malaise—Epirubicin—liver cancer	0.000286	0.00128	CcSEcCtD
Entacapone—Nervousness—Doxorubicin—liver cancer	0.000285	0.00127	CcSEcCtD
Entacapone—Vertigo—Epirubicin—liver cancer	0.000285	0.00127	CcSEcCtD
Entacapone—Syncope—Epirubicin—liver cancer	0.000284	0.00127	CcSEcCtD
Entacapone—Leukopenia—Epirubicin—liver cancer	0.000284	0.00127	CcSEcCtD
Entacapone—Back pain—Doxorubicin—liver cancer	0.000284	0.00127	CcSEcCtD
Entacapone—Muscle spasms—Doxorubicin—liver cancer	0.000282	0.00126	CcSEcCtD
Entacapone—Palpitations—Epirubicin—liver cancer	0.00028	0.00125	CcSEcCtD
Entacapone—Loss of consciousness—Epirubicin—liver cancer	0.000278	0.00124	CcSEcCtD
Entacapone—Cough—Epirubicin—liver cancer	0.000276	0.00124	CcSEcCtD
Entacapone—Vision blurred—Doxorubicin—liver cancer	0.000276	0.00123	CcSEcCtD
Entacapone—Convulsion—Epirubicin—liver cancer	0.000274	0.00123	CcSEcCtD
Entacapone—COMT—Neuronal System—BRAF—liver cancer	0.000274	0.00162	CbGpPWpGaD
Entacapone—Hypertension—Epirubicin—liver cancer	0.000273	0.00122	CcSEcCtD
Entacapone—Ill-defined disorder—Doxorubicin—liver cancer	0.000272	0.00122	CcSEcCtD
Entacapone—Myalgia—Epirubicin—liver cancer	0.00027	0.0012	CcSEcCtD
Entacapone—Chest pain—Epirubicin—liver cancer	0.00027	0.0012	CcSEcCtD
Entacapone—Agitation—Doxorubicin—liver cancer	0.000269	0.0012	CcSEcCtD
Entacapone—Anxiety—Epirubicin—liver cancer	0.000269	0.0012	CcSEcCtD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000268	0.0012	CcSEcCtD
Entacapone—Discomfort—Epirubicin—liver cancer	0.000266	0.00119	CcSEcCtD
Entacapone—Malaise—Doxorubicin—liver cancer	0.000264	0.00118	CcSEcCtD
Entacapone—Dry mouth—Epirubicin—liver cancer	0.000264	0.00118	CcSEcCtD
Entacapone—Vertigo—Doxorubicin—liver cancer	0.000263	0.00118	CcSEcCtD
Entacapone—Syncope—Doxorubicin—liver cancer	0.000263	0.00117	CcSEcCtD
Entacapone—Leukopenia—Doxorubicin—liver cancer	0.000262	0.00117	CcSEcCtD
Entacapone—Confusional state—Epirubicin—liver cancer	0.000261	0.00116	CcSEcCtD
Entacapone—Palpitations—Doxorubicin—liver cancer	0.000259	0.00116	CcSEcCtD
Entacapone—Oedema—Epirubicin—liver cancer	0.000259	0.00116	CcSEcCtD
Entacapone—Loss of consciousness—Doxorubicin—liver cancer	0.000258	0.00115	CcSEcCtD
Entacapone—Cough—Doxorubicin—liver cancer	0.000256	0.00114	CcSEcCtD
Entacapone—Shock—Epirubicin—liver cancer	0.000254	0.00114	CcSEcCtD
Entacapone—Convulsion—Doxorubicin—liver cancer	0.000254	0.00113	CcSEcCtD
Entacapone—Nervous system disorder—Epirubicin—liver cancer	0.000254	0.00113	CcSEcCtD
Entacapone—Thrombocytopenia—Epirubicin—liver cancer	0.000253	0.00113	CcSEcCtD
Entacapone—Hypertension—Doxorubicin—liver cancer	0.000253	0.00113	CcSEcCtD
Entacapone—Skin disorder—Epirubicin—liver cancer	0.000251	0.00112	CcSEcCtD
Entacapone—Hyperhidrosis—Epirubicin—liver cancer	0.00025	0.00112	CcSEcCtD
Entacapone—Chest pain—Doxorubicin—liver cancer	0.00025	0.00111	CcSEcCtD
Entacapone—Myalgia—Doxorubicin—liver cancer	0.00025	0.00111	CcSEcCtD
Entacapone—Anxiety—Doxorubicin—liver cancer	0.000249	0.00111	CcSEcCtD
Entacapone—COMT—Metabolism—CPT1B—liver cancer	0.000248	0.00147	CbGpPWpGaD
Entacapone—COMT—Metabolism—GLUL—liver cancer	0.000248	0.00147	CbGpPWpGaD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000248	0.00111	CcSEcCtD
Entacapone—Discomfort—Doxorubicin—liver cancer	0.000247	0.0011	CcSEcCtD
Entacapone—Anorexia—Epirubicin—liver cancer	0.000246	0.0011	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000246	0.00146	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—UGDH—liver cancer	0.000246	0.00145	CbGpPWpGaD
Entacapone—Dry mouth—Doxorubicin—liver cancer	0.000244	0.00109	CcSEcCtD
Entacapone—Hypotension—Epirubicin—liver cancer	0.000242	0.00108	CcSEcCtD
Entacapone—Confusional state—Doxorubicin—liver cancer	0.000241	0.00108	CcSEcCtD
Entacapone—COMT—Metabolism—NR1H4—liver cancer	0.00024	0.00142	CbGpPWpGaD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—liver cancer	0.000239	0.00142	CbGpPWpGaD
Entacapone—Oedema—Doxorubicin—liver cancer	0.000239	0.00107	CcSEcCtD
Entacapone—COMT—Metabolism—GSTA3—liver cancer	0.000236	0.00139	CbGpPWpGaD
Entacapone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000236	0.00105	CcSEcCtD
Entacapone—Shock—Doxorubicin—liver cancer	0.000235	0.00105	CcSEcCtD
Entacapone—Nervous system disorder—Doxorubicin—liver cancer	0.000235	0.00105	CcSEcCtD
Entacapone—Thrombocytopenia—Doxorubicin—liver cancer	0.000234	0.00105	CcSEcCtD
Entacapone—Insomnia—Epirubicin—liver cancer	0.000234	0.00104	CcSEcCtD
Entacapone—Skin disorder—Doxorubicin—liver cancer	0.000232	0.00104	CcSEcCtD
Entacapone—Paraesthesia—Epirubicin—liver cancer	0.000232	0.00104	CcSEcCtD
Entacapone—Hyperhidrosis—Doxorubicin—liver cancer	0.000231	0.00103	CcSEcCtD
Entacapone—UGT1A9—Metabolism—EPT1—liver cancer	0.000231	0.00137	CbGpPWpGaD
Entacapone—Dyspnoea—Epirubicin—liver cancer	0.00023	0.00103	CcSEcCtD
Entacapone—Somnolence—Epirubicin—liver cancer	0.00023	0.00103	CcSEcCtD
Entacapone—COMT—Neuronal System—RAF1—liver cancer	0.000229	0.00135	CbGpPWpGaD
Entacapone—Anorexia—Doxorubicin—liver cancer	0.000228	0.00102	CcSEcCtD
Entacapone—Dyspepsia—Epirubicin—liver cancer	0.000228	0.00102	CcSEcCtD
Entacapone—Decreased appetite—Epirubicin—liver cancer	0.000225	0.001	CcSEcCtD
Entacapone—Hypotension—Doxorubicin—liver cancer	0.000224	0.000999	CcSEcCtD
Entacapone—Gastrointestinal disorder—Epirubicin—liver cancer	0.000223	0.000997	CcSEcCtD
Entacapone—Fatigue—Epirubicin—liver cancer	0.000223	0.000996	CcSEcCtD
Entacapone—Constipation—Epirubicin—liver cancer	0.000221	0.000988	CcSEcCtD
Entacapone—Pain—Epirubicin—liver cancer	0.000221	0.000988	CcSEcCtD
Entacapone—UGT1A9—Metabolism—TAT—liver cancer	0.000219	0.0013	CbGpPWpGaD
Entacapone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000218	0.000974	CcSEcCtD
Entacapone—Insomnia—Doxorubicin—liver cancer	0.000216	0.000967	CcSEcCtD
Entacapone—COMT—Metabolism—GSTA4—liver cancer	0.000215	0.00127	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000215	0.00127	CbGpPWpGaD
Entacapone—Paraesthesia—Doxorubicin—liver cancer	0.000215	0.00096	CcSEcCtD
Entacapone—Dyspnoea—Doxorubicin—liver cancer	0.000213	0.000953	CcSEcCtD
Entacapone—Feeling abnormal—Epirubicin—liver cancer	0.000213	0.000952	CcSEcCtD
Entacapone—Somnolence—Doxorubicin—liver cancer	0.000213	0.00095	CcSEcCtD
Entacapone—Gastrointestinal pain—Epirubicin—liver cancer	0.000211	0.000945	CcSEcCtD
Entacapone—Dyspepsia—Doxorubicin—liver cancer	0.000211	0.000941	CcSEcCtD
Entacapone—COMT—Metabolism—GSTA2—liver cancer	0.00021	0.00124	CbGpPWpGaD
Entacapone—Decreased appetite—Doxorubicin—liver cancer	0.000208	0.000929	CcSEcCtD
Entacapone—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000207	0.000923	CcSEcCtD
Entacapone—Fatigue—Doxorubicin—liver cancer	0.000206	0.000921	CcSEcCtD
Entacapone—Urticaria—Epirubicin—liver cancer	0.000205	0.000918	CcSEcCtD
Entacapone—Constipation—Doxorubicin—liver cancer	0.000205	0.000914	CcSEcCtD
Entacapone—Pain—Doxorubicin—liver cancer	0.000205	0.000914	CcSEcCtD
Entacapone—Abdominal pain—Epirubicin—liver cancer	0.000204	0.000913	CcSEcCtD
Entacapone—Body temperature increased—Epirubicin—liver cancer	0.000204	0.000913	CcSEcCtD
Entacapone—COMT—Metabolism—GSTA1—liver cancer	0.000203	0.0012	CbGpPWpGaD
Entacapone—COMT—Metabolism—NAT2—liver cancer	0.0002	0.00118	CbGpPWpGaD
Entacapone—Feeling abnormal—Doxorubicin—liver cancer	0.000197	0.000881	CcSEcCtD
Entacapone—Gastrointestinal pain—Doxorubicin—liver cancer	0.000196	0.000874	CcSEcCtD
Entacapone—COMT—Metabolism—ALDOB—liver cancer	0.000192	0.00114	CbGpPWpGaD
Entacapone—Hypersensitivity—Epirubicin—liver cancer	0.00019	0.000851	CcSEcCtD
Entacapone—Urticaria—Doxorubicin—liver cancer	0.00019	0.000849	CcSEcCtD
Entacapone—Abdominal pain—Doxorubicin—liver cancer	0.000189	0.000845	CcSEcCtD
Entacapone—Body temperature increased—Doxorubicin—liver cancer	0.000189	0.000845	CcSEcCtD
Entacapone—Asthenia—Epirubicin—liver cancer	0.000185	0.000829	CcSEcCtD
Entacapone—COMT—Metabolism—CRABP1—liver cancer	0.000183	0.00108	CbGpPWpGaD
Entacapone—Pruritus—Epirubicin—liver cancer	0.000183	0.000817	CcSEcCtD
Entacapone—Diarrhoea—Epirubicin—liver cancer	0.000177	0.00079	CcSEcCtD
Entacapone—Hypersensitivity—Doxorubicin—liver cancer	0.000176	0.000787	CcSEcCtD
Entacapone—Asthenia—Doxorubicin—liver cancer	0.000172	0.000767	CcSEcCtD
Entacapone—Dizziness—Epirubicin—liver cancer	0.000171	0.000764	CcSEcCtD
Entacapone—Pruritus—Doxorubicin—liver cancer	0.000169	0.000756	CcSEcCtD
Entacapone—COMT—Transmission across Chemical Synapses—HRAS—liver cancer	0.000165	0.000973	CbGpPWpGaD
Entacapone—Vomiting—Epirubicin—liver cancer	0.000164	0.000734	CcSEcCtD
Entacapone—Diarrhoea—Doxorubicin—liver cancer	0.000164	0.000731	CcSEcCtD
Entacapone—Rash—Epirubicin—liver cancer	0.000163	0.000728	CcSEcCtD
Entacapone—Dermatitis—Epirubicin—liver cancer	0.000163	0.000728	CcSEcCtD
Entacapone—Headache—Epirubicin—liver cancer	0.000162	0.000724	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000161	0.000953	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—TGFB1—liver cancer	0.000161	0.000952	CbGpPWpGaD
Entacapone—COMT—Metabolism—HPGDS—liver cancer	0.00016	0.000947	CbGpPWpGaD
Entacapone—Dizziness—Doxorubicin—liver cancer	0.000158	0.000707	CcSEcCtD
Entacapone—Nausea—Epirubicin—liver cancer	0.000154	0.000686	CcSEcCtD
Entacapone—Vomiting—Doxorubicin—liver cancer	0.000152	0.00068	CcSEcCtD
Entacapone—Rash—Doxorubicin—liver cancer	0.000151	0.000674	CcSEcCtD
Entacapone—Dermatitis—Doxorubicin—liver cancer	0.000151	0.000673	CcSEcCtD
Entacapone—Headache—Doxorubicin—liver cancer	0.00015	0.00067	CcSEcCtD
Entacapone—UGT1A9—Metabolism—GLUL—liver cancer	0.000149	0.00088	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CPT1B—liver cancer	0.000149	0.00088	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—NR1H4—liver cancer	0.000144	0.000849	CbGpPWpGaD
Entacapone—COMT—Metabolism—PSMA4—liver cancer	0.000143	0.000844	CbGpPWpGaD
Entacapone—COMT—Metabolism—PSMD10—liver cancer	0.000143	0.000844	CbGpPWpGaD
Entacapone—Nausea—Doxorubicin—liver cancer	0.000142	0.000635	CcSEcCtD
Entacapone—UGT1A9—Metabolism—GSTA3—liver cancer	0.000141	0.000835	CbGpPWpGaD
Entacapone—COMT—Metabolism—GOT2—liver cancer	0.000139	0.000821	CbGpPWpGaD
Entacapone—COMT—Metabolism—CYP2E1—liver cancer	0.000131	0.000772	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTA4—liver cancer	0.000129	0.000763	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.000126	0.000746	CbGpPWpGaD
Entacapone—COMT—Neuronal System—HRAS—liver cancer	0.000126	0.000746	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTA2—liver cancer	0.000126	0.000744	CbGpPWpGaD
Entacapone—COMT—Metabolism—CYCS—liver cancer	0.000122	0.000722	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTA1—liver cancer	0.000121	0.000718	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—NAT2—liver cancer	0.00012	0.00071	CbGpPWpGaD
Entacapone—COMT—Metabolism—GGT1—liver cancer	0.00012	0.000709	CbGpPWpGaD
Entacapone—COMT—Metabolism—GOT1—liver cancer	0.00012	0.000709	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000115	0.000682	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ALDOB—liver cancer	0.000115	0.00068	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CRABP1—liver cancer	0.00011	0.000649	CbGpPWpGaD
Entacapone—COMT—Metabolism—GSTP1—liver cancer	0.000108	0.000637	CbGpPWpGaD
Entacapone—COMT—Metabolism—HMOX1—liver cancer	0.000106	0.000628	CbGpPWpGaD
Entacapone—COMT—Metabolism—GSTM1—liver cancer	9.89e-05	0.000585	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	9.88e-05	0.000584	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—HPGDS—liver cancer	9.59e-05	0.000567	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	9.54e-05	0.000564	CbGpPWpGaD
Entacapone—COMT—Metabolism—CYP1A1—liver cancer	9.38e-05	0.000555	CbGpPWpGaD
Entacapone—COMT—Metabolism—MTHFR—liver cancer	8.74e-05	0.000517	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.69e-05	0.000514	CbGpPWpGaD
Entacapone—COMT—Metabolism—PPARA—liver cancer	8.58e-05	0.000507	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.57e-05	0.000507	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PSMA4—liver cancer	8.55e-05	0.000506	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PSMD10—liver cancer	8.55e-05	0.000506	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GOT2—liver cancer	8.32e-05	0.000492	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CYP2E1—liver cancer	7.82e-05	0.000462	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.57e-05	0.000448	CbGpPWpGaD
Entacapone—COMT—Metabolism—PIK3CG—liver cancer	7.35e-05	0.000434	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CYCS—liver cancer	7.32e-05	0.000433	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GOT1—liver cancer	7.18e-05	0.000425	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GGT1—liver cancer	7.18e-05	0.000425	CbGpPWpGaD
Entacapone—COMT—Metabolism—PPARG—liver cancer	7.09e-05	0.000419	CbGpPWpGaD
Entacapone—COMT—Metabolism—PIK3CD—liver cancer	6.46e-05	0.000382	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTP1—liver cancer	6.45e-05	0.000381	CbGpPWpGaD
Entacapone—COMT—Metabolism—ALB—liver cancer	6.37e-05	0.000377	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—HMOX1—liver cancer	6.36e-05	0.000376	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTM1—liver cancer	5.93e-05	0.00035	CbGpPWpGaD
Entacapone—COMT—Metabolism—PIK3CB—liver cancer	5.63e-05	0.000333	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CYP1A1—liver cancer	5.62e-05	0.000332	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—MTHFR—liver cancer	5.24e-05	0.00031	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PPARA—liver cancer	5.14e-05	0.000304	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.62e-05	0.000273	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PIK3CG—liver cancer	4.4e-05	0.00026	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PPARG—liver cancer	4.25e-05	0.000251	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PIK3CD—liver cancer	3.87e-05	0.000229	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ALB—liver cancer	3.82e-05	0.000226	CbGpPWpGaD
Entacapone—COMT—Metabolism—PIK3CA—liver cancer	3.43e-05	0.000203	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PIK3CB—liver cancer	3.37e-05	0.000199	CbGpPWpGaD
Entacapone—COMT—Metabolism—AKT1—liver cancer	2.8e-05	0.000166	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PIK3CA—liver cancer	2.06e-05	0.000122	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—AKT1—liver cancer	1.68e-05	9.93e-05	CbGpPWpGaD
